Genmab A/S Stock

Genmab A/S Equity Turnover

The Equity Turnover of Genmab A/S (GMAB.CO) as of Aug 10, 2026 is 0.64. In the previous year, Equity Turnover was 0.61 — a change of 3.83% (higher).

Equity Turnover

0.64

YoY

3.83%

Last updated:

Equity Turnover of Genmab A/S is 2026 0.64 . Equity Turnover of Genmab A/S was 2025 0.61 . It decreases by 3.83% higher compared to the previous year.
Access this data via the Eulerpool API

Genmab A/S Stock analysis

What does Genmab A/S do? Genmab A/S is a Danish biotechnology company specializing in the discovery and development of antibody therapies for cancer and other serious diseases. The company was founded in 1999 and is headquartered in Copenhagen, Denmark. Genmab A/S is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Genmab A/S stock

Equity Turnover of Genmab A/S is 0.64 in 2026.

Equity Turnover of Genmab A/S changed from 0.61 to 0.64, representing a 3.83% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of Equity Turnover Genmab A/S since 2006 – with annual values, charts, and detailed analysis.

Equity turnover measures how efficiently a company uses shareholders' equity to generate revenue. It is a component of the DuPont analysis framework.

A 'good' varies by industry and company stage. On Eulerpool, you can compare Equity Turnover's Genmab A/S with sector peers and the industry average to assess whether it is attractive.

To evaluate Equity Turnover's, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for Equity Turnover.

Access this data via the Eulerpool API

Profitability — Genmab A/S

All Key Metrics — Genmab A/S